Use of oligosaccharide compounds for the prevention and treatment of pathological scars

A compound and pathological technology, applied in skin care preparations, medical preparations containing active ingredients, cosmetics, etc., can solve the problem of wounds that cannot produce hypertrophic scars

Inactive Publication Date: 2014-04-16
URGO RECH INNOVATION & DEVEMENT +1
View PDF9 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the wounds studied in said literatu

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of oligosaccharide compounds for the prevention and treatment of pathological scars
  • Use of oligosaccharide compounds for the prevention and treatment of pathological scars
  • Use of oligosaccharide compounds for the prevention and treatment of pathological scars

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0131] Example 1: Effects of Sucrose Octasulfate Potassium Salt (KSOS) on Myofibroblast Differentiation proof of

[0132] 1. Culture of normal human dermal fibroblasts (NHDF)

[0133] DMEM / F12 medium (marketed by Invitrogen) supplemented with 10% fetal bovine serum (marketed by Invitrogen), 5 μg / ml of insulin (marketed by Promokine) and 1 ng / ml of bFGF (marketed by Promokine) ) cultures of normal human dermal fibroblasts (NHDF).

[0134] 2. induced differentiation

[0135] Then, the fibroblasts are induced to differentiate into myofibroblasts.

[0136] To this end, NHDF cultures were placed on P100 dishes coated with 5 μg / ml collagen in DMEM / F12 medium supplemented with 10% fetal bovine serum and supplemented with 10 ng / ml ml of TGF-β (marketed by Promocell), which is a growth factor that controls cell proliferation and differentiation (differentiation control in Figure 1).

[0137] In addition, cultures in DMEM / F12 supplemented with 10% fetal calf serum but withou...

Embodiment 2

[0148] Example 2: Effect of Potassium Sucrose Octasulfate (KSOS) on Collagen Lattice Contraction proof of

[0149] 1. Preparation of Collagen Lattice

[0150] By inoculating 0.8 × 10 gels with type I collagen at a final concentration of 1.3 mg / ml 6 normal human dermal fibroblasts (NHDF) to obtain collagen lattices.

[0151] 2. Demonstration of the effect of potassium sucrose octasulfate (KSOS) on collagen lattice contraction

[0152] A dressing containing 7.5% potassium sucrose octasulfate (sold under the trade name Urgotul Start) was applied to the surface of the collagen lattice.

[0153] To evaluate the normal contraction of collagen gels induced by inoculated NHDF, a control series without dressing was performed.

[0154] Also, in order to visualize the strong contraction induced by NHDF of highly differentiated myofibroblastic cells, a positive control was performed by adding TGF-β at a concentration of 10 ng / ml.

[0155] The incubation was maintained up to 7 ...

Embodiment 3

[0163] A solvent-based filmogel-type formulation comprising a synthetic polysulfated oligosaccharide according to the invention was prepared having the following composition:

[0164] components

[0165] Dilute the nitrocellulose in a mixture of ethyl acetate / absolute ethanol. Castor oil, UV screener and KSOS are then added until dissolved to obtain a filmogel type composition.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention relates to a compound selected among the synthetic polysulphated oligosaccharides having 1 to 4 ose units and the salts and complexes thereof to be used for the treatment of wounds resulting in pathological scars selected among hypertrophic, retractile or atrophic scars. Said use is preferred in particular in patients that have a predisposition to developing hypertrophic, retractile or atrophic scars. According to a second aspect, the invention also relates to said compound for the use thereof in order to inhibit the differentiation of fibroblasts into myofibroblasts during the cicatrisation of wounds resulting in pathological scars selected among hypertrophic, retractile or atrophic scars.

Description

technical field [0001] The subject of the present invention is a compound selected from synthetic polysulfated oligosaccharides having 1-4 monosaccharide units, their salts or their complexes for use in the treatment of wounds producing pathological scars. Background technique [0002] Wound healing is a natural biological phenomenon in which human and animal tissues are able to repair local damage through their specific repair and regeneration processes. [0003] The speed and quality of wound healing depend on the overall condition of the affected organism, the etiology of the wound, the condition and location of the wound, possible infections, and genetic factors that may predispose to impaired healing. [0004] The natural healing of wounds proceeds primarily in three sequential phases, each of which is characterized by specific cellular events that keep the repair process in a precise chronological order: the inflammatory phase, the granulation phase (or hyperplastic ph...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K8/60A61K31/7016A61L15/16A61Q19/00A61P17/02A61L15/22A61L15/44
CPCA61K8/891A61K9/0014A61K8/342A61K31/513A61K8/375A61L2300/232A61K9/7015A61L15/16A61L15/44A61K8/361A61L2300/412A61K8/60A61L15/28A61K31/7016A61K31/415A61Q19/00A61K8/37A61L15/22A61P17/00A61P17/02A61P17/04A61P17/16A61P25/04A61P25/20A61P29/00A61P31/04A61P39/06A61P43/00
Inventor M·布施巴舍尔C·洛朗苏
Owner URGO RECH INNOVATION & DEVEMENT
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap